Rapid progression from lower limb cellulitis to fatal sepsis in an immunocompetent young patient
MRIMS Journal of Health Sciences · 2026-04 · 14 (2) · 162-164
DOI: 10.4103/mjhs.mjhs_69_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift MRIMS Journal of Health Sciences, online erschienen am 06.04.2026. Verfasst von Aishwarya Babu und 3 weiteren Autor:innen. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Sepsis
Abstract (Originalsprache)
Melioidosis is caused by virulent Gram-negative bacilli, Burkholderia pseudomallei , which is ubiquitous in soil and water. Here, we report a case of rapid progression of cellulitis to fatal sepsis caused by B . pseudomallei in a previously healthy 27-year-old male. Despite aggressive resuscitation and antibiotic therapy, the patient succumbed to his illness within 48 h of admission. This case report highlights the challenge in diagnosing melioidosis due to its variable clinical presentation. Furthermore, in India majority of the cases of melioidosis that have been reported from patients with diabetes mellitus or other immunocompromised conditions, whereas our patient is a young immunocompetent individual.
Zitieren
APA
Babu, A., Paul, S., Thakar, V., & Modak, M. (2026). Rapid progression from lower limb cellulitis to fatal sepsis in an immunocompetent young patient. MRIMS Journal of Health Sciences, 14(2), 162-164. https://doi.org/10.4103/mjhs.mjhs_69_25
Vancouver
Babu A, Paul S, Thakar V, Modak M. Rapid progression from lower limb cellulitis to fatal sepsis in an immunocompetent young patient. MRIMS Journal of Health Sciences. 2026;14(2):162-164. doi:10.4103/mjhs.mjhs_69_25
BibTeX
@article{Babu2026,
author = {Babu, Aishwarya and Paul, Sania and Thakar, Vrushali and Modak, Meera},
title = {Rapid progression from lower limb cellulitis to fatal sepsis in an immunocompetent young patient},
journal = {MRIMS Journal of Health Sciences},
year = {2026},
volume = {14},
number = {2},
pages = {162--164},
doi = {10.4103/mjhs.mjhs_69_25}
}
EUVIMED